Analysis of programmed death-ligand 1 expression in primary normal human dermal fibroblasts after DNA damage

Iwai, 2017, Cancer immunotherapies targeting the PD-1 signaling pathway, J. Biomed. Sci., 24, 26, 10.1186/s12929-017-0329-9 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N. Engl. J. Med., 372, 320, 10.1056/NEJMoa1412082 Wang, 2017, Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis, Oncotarget, 8, 59901, 10.18632/oncotarget.18316 Llosa, 2015, The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov., 5, 43, 10.1158/2159-8290.CD-14-0863 Rosenbaum, 2016, PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes, Mod. Pathol., 29, 1104, 10.1038/modpathol.2016.95 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 Deng, 2014, Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice, J. Clin. Invest., 124, 687, 10.1172/JCI67313 Harding, 2017, Mitotic progression following DNA damage enables pattern recognition within micronuclei, Nature, 548, 466, 10.1038/nature23470 Mackenzie, 2017, cGAS surveillance of micronuclei links genome instability to innate immunity, Nature, 548, 461, 10.1038/nature23449 Sato, 2017, DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells, Nat. Commun., 8, 1751, 10.1038/s41467-017-01883-9 Nakajima, 2017, Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain A and B in cancer cells, Oncol. Rep., 10.3892/or.2017.5773 Gaszner, 2006, Insulators: exploiting transcriptional and epigenetic mechanisms, Nat. Rev. Genet., 7, 703, 10.1038/nrg1925 Eppihimer, 2002, Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells, Microcirculation, 9, 133, 10.1080/713774061 Wang, 2005, Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes, Proc. Natl. Acad. Sci. U.S.A., 102, 11823, 10.1073/pnas.0505497102 Baragano Raneros, 2015, Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia, Genes Immun., 16, 71, 10.1038/gene.2014.58 Woods, 2015, HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade, Cancer Immunol. Res., 3, 1375, 10.1158/2326-6066.CIR-15-0077-T West, 2014, New and emerging HDAC inhibitors for cancer treatment, J. Clin. Invest., 124, 30, 10.1172/JCI69738 Parsa, 2007, Loss of tumor suppressor PTEN function increases B7–H1 expression and immunoresistance in glioma, Nat. Med., 13, 84, 10.1038/nm1517 Mittendorf, 2014, PD-L1 expression in triple-negative breast cancer, Cancer Immunol. Res., 2, 361, 10.1158/2326-6066.CIR-13-0127